BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company developing orally bioavailable small molecule inhibitors for cancers driven by RAS and PI3Kα mutations. The company's pipeline consists of three precision oncology assets: BBO-8520, a dual KRAS G12C ON/OFF inhibitor; BBO-11818, a pan-KRAS ON/OFF inhibitor; and BBO-10203, a RAS:PI3Kα Breaker that blocks RAS-dependent activation of PI3Kα. These therapies target patients with non-small cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer. The company is currently advancing Phase 1 clinical trials, including ONKORAS-101, KONQUER-101, and BREAKER-101, evaluating these compounds as monotherapies and in combination with standard treatments such as pembrolizumab, trastuzumab, and fulvestrant. BridgeBio Oncology Therapeutics focuses on achieving high levels of target inhibition while maintaining a favorable tolerability profile, specifically aiming to avoid side effects like hyperglycemia associated with other PI3Kα inhibitors.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage bbotx.com
Sector Healthcare IR page investors.bbotx.com
Tags
oncology, small molecule inhibitors, kras inhibitors, pi3kα inhibitors, precision medicine, lung cancer, breast cancer, colorectal cancer, pancreatic cancer, clinical-stage, BBO-8520, BBO-11818, BBO-10203, ONKORAS-101, KONQUER-101, BREAKER-101
Press page —

Metrics

Valuation  
Market cap $ 190.156M
Market cap (USD) $ 190.156M
P/E -1.11
PEG —
P/BV 0.65
P/S —
P/OCF -2.11
P/FCF -1.66
Dividend yield —
Turnover / mcap —
Returns  
ROE -32.6%
ROI -338.0%
ROIC -275.8%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -72.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023
Assets 448.381M 164.301M 5.942M
Net profit -134.044M -74.275M -64.699M
Free cash flow -114.5M -55.076M -52.493M

Figure FY 2025 FY 2024 FY 2023
Share price 12.52 10.5 —
Price performance 12m 0.19 — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 0.00 2.77M
Cash and deposits (USD) 250,000 1.7M 374M
Right-of-use assets (USD) — 0.00 2.33M
Cash flow detail
Operating cash flow (USD) — -763,820 -114M
Purchases of property, plant and equipment (USD) — -49,000 -606,000
Change in payables (cash effect) (USD) 15,000 104,706 -1.84M
Share-based compensation (USD) — 271,572 5.87M
Free cash flow (OCF - PPE - intangibles) (USD) — -55.1M -115M
Income detail
Research and development expense (USD) — 73.1M 121M
Total comprehensive income (USD) — -73.9M -134M
Comprehensive income to owners (USD) — -73.9M -134M
Reported Nov 12, 2025 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients

•BBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC); BBO-11818 and BBO-10203 monotherapy data update expected in the fourth quarter of 2026

•Cash runway expected to fund operations into 2029

SOUTH SAN FRANCISCO, Calif., November 10, 2026 — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the quarter ended September 30, 2026, and provided a business update.

BBOT’s portfolio of RAS-pathway inhibitors is designed to enable direct dual inhibition of KRASG12C (BBO-8520), or KRASG12D/V (BBO-11818) in both their ON and OFF states as well as disruption of RAS-driven PI3Kα activation (BBO-10203) to achieve optimal target coverage of the most mutated driver oncogene in human cancer.

(b) On October 30, 2026, Yong Ben, M.D., M.B.A. provided notice of his resignation as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc. (the “Company”), effective January 8, 2027. Dr. Ben’s resignation was not due to any disagreement regarding the operations, policies or practices of the Company.

October 12, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.

The employee received non-qualified stock options to purchase an aggregate 90,000 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $3.31 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the last trading day prior to the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts: Investor Contact: BBOT [email protected] Media Contact: Jake Robison Inizio Evoke Comms [email protected]

Scroll to top

Cookie and Privacy Settings

How we use cookies

Essential Website Cookies

Other external services

Privacy Policy

How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Prompts

BridgeBio Oncology Therapeutics, Inc. (ticker BBOT), listed in United States.

Company History

Date Change Detail
May 13, 2025 Renamed HELIX ACQUISITION CORP. II → BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

ETFs Holding BridgeBio Oncology Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.41% 97,750 $ 860.2K Aug 31, 2026
DFSU 0.00% 3,678 $ 8,643.30 Nov 12, 2026
DFAS 0.00% 4,229 $ 9,938.15 Nov 12, 2026
DCOR 0.00% 2,893 $ 6,798.55 Nov 12, 2026